截至目前,引用Bioss产品发表的文献共23073篇,总影响因子105342.2分,发表在Nature, Science, Cell以及Immunity等顶级期刊的文献共54篇,合作单位覆盖了清华、北大、复旦、华盛顿大学、麻省理工学院、东京大学以及纽约大学等国际研究机构上百所。
我们每月收集引用Bioss产品发表的文献。若您在当月已发表SCI文章,但未被我公司收集,请致电Bioss,我们将赠予现金鼓励,金额标准请参考“发文章 领奖金”活动页面。
近期收录2022年11月引用Bioss产品发表的文献共284篇(图一,绿色柱),文章影响因子(IF) 总和高达1886.766,其中,10分以上文献43篇(图二)。
图一
图二
本文主要分享引用Bioss产品发表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的6篇 IF>15 的文献摘要,让我们一起欣赏吧。
ADVANCED MATERIALS
[IF=32.086]
作者单位:广东省传感器技术与生物医学仪器重点实验室中山大学生物医学工程学院深圳校区中山大学深圳分校
JOURNAL OF MEDICAL VIROLOGY
[IF=20.693]
文献引用抗体:
bsk11014; Human TNF-α ELISA KIT; ELISA
bsk11007; Human IL-6 ELISA KIT; ELISA
摘要:Lots of epidemiological and clinical studies have shown that human cytomegalovirus (HCMV) is related to the pathogenesis of atherosclerosis. Released by inflammatory cells and vascular smooth muscle cell (VSMCs), metalloproteinases are observed in many pathological vessel conditions, including atherosclerosis and restenosis. This study was designed to investigate the effect of HCMV infection on the expression of metalloproteinases and their involvements in the HCMV-induced functional changes of VSMCs. Differential metalloproteinase after HCMV infection was assayed using reverse transcription-polymerase chain reaction (RT-PCR) microarray.
MOLECULAR CELL
[IF=19.328]
Anti-MDH1 pAb; WB
Nature Communications
[IF=17.694]
文献引用抗体:bs-11462R
Anti-BCAS1 pAb; IF
Nature Communications
[IF=17.694]
文献引用抗体:
bs-0296G-FITC; Goat Anti-Mouse IgG H&L / FITC antibody; IF
bs-0521R-FITC; Anti-CD44/FITC pAb;IF
C05-07004; BiossECL Plus WB Substrate
作者单位:中国南京东南大学生物科学与医学工程学院生物电子学国家重点实验室
摘要:Cancer vaccine, which can promote tumor-specific immunostimulation, is one of the most important immunotherapeutic strategies and holds tremendous potential for cancer treatment/prevention. Here, we prepare a series of nanoparticles composed of doxorubicin- and tyrosine kinase inhibitor-loaded and hyaluronic acid-coated dendritic polymers (termed HDDT nanoparticles) and find that the HDDT nanoparticles can convert various cancer cells to micrometer-sized vesicles (1.6−3.2 μm; termed HMVs) with ~100% cell-to-HMV conversion efficiency. We confirm in two tumor-bearing mouse models that the nanoparticles can restrain tumor growth, induce robust immunogenic cell death, and convert the primary tumor into an antigen depot by producing HMVs in situ to serve as personalized vaccines for cancer immunotherapy. Furthermore, the HDDT-healed mice show a strong immune memory effect and the HDDT treatment can realize long-term protection against tumor rechallenge. Collectively, the present work provides a general strategy for the preparation of tumor-associated antigen-containing vesicles and the development of personalized cancer vaccines.
Nature Communications
[IF=17.694]
文献引用抗体:bs-0437P-AF555
Streptavidin / AF555
作者单位:北京大学口腔医学院老年牙科系
摘要:RIG-I/DDX58 plays a key role in host innate immunity. However, its therapeutic potential for inflammation-related cancers remains to be explored. Here we identify frameshift germline mutations of RIG-I occurring in patients with colon cancer. Accordingly, Rig-ifs/fs mice bearing a frameshift mutant Rig-i exhibit increased susceptibility to colitis-related colon cancer as well as enhanced inflammatory response to chemical, virus or bacteria. In addition to interruption of Rig-i mRNA translation, the Rig-i mutation changes the secondary structure of Rig-i pre-mRNA and impairs its association with DHX9, consequently inducing a circular RNA generation from Rig-i transcript, thereby, designated as circRIG-I. CircRIG-I is frequently upregulated in colon cancers and its upregulation predicts poor outcome of colon cancer. Mechanistically, circRIG-I interacts with DDX3X, which in turn stimulates MAVS/TRAF5/TBK1 signaling cascade, eventually activating IRF3-mediated type I IFN transcription and aggravating inflammatory damage. Reciprocally, all-trans retinoic acid acts as a DHX9 agonist, ameliorates immunopathology through suppression of circRIG-I biogenesis. Collectively, our results provide insight into mutant RIG-I action and propose a potential strategy for the treatment of colon cancer.